Meeting
2023 ASCO Annual Meeting
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.
Authors
Melissa Lynne Johnson
Lung Cancer Research, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN
Melissa Lynne Johnson , Jason Timothy Henry , Alexander I. Spira , James Battiste , Iyad Alnahhas , Manmeet Singh Ahluwalia , Minal A. Barve , William Jeffery Edenfield , Do-Hyun Nam , Sudharshan Eathiraj , Julio Hajdenberg , Sergey Yurasov , Helena Alexandra Yu , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05256290
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9156)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9156
Abstract #
TPS9156
Poster Bd #
135b
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
First Author: Hui Kong Gan
Poster
2023 ASCO Annual Meeting
Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.
First Author: Carlos Pedraz
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura